Core Viewpoint - The establishment of the Fudan University Zhongshan Hospital Heart Valve Disease Treatment Center marks a significant advancement in the diagnosis and treatment of heart valve diseases in China, emphasizing a multidisciplinary approach to patient care [1][7][10]. Group 1: Heart Valve Disease Overview - Heart valve disease is a common yet complex cardiovascular condition affecting the heart's valve structures, leading to serious complications such as heart failure and arrhythmias [3][5]. - The prevalence of heart valve disease in China is approximately 3.8%, equating to around 25 million patients, with a notable increase in risk for individuals over 60 years old [5][10]. Group 2: Treatment Innovations - Advances in medical technology have shifted treatment strategies from traditional open surgery to minimally invasive procedures and transcatheter interventions, allowing for earlier intervention in high-risk patients [5][10]. - The Zhongshan Hospital Heart Valve Disease Center integrates various medical disciplines to create a comprehensive treatment model, enhancing the efficiency of care for critically ill patients [7][9]. Group 3: Center's Achievements and Future Plans - Since its establishment, the center has performed nearly 1,000 interventional valve surgeries and over 1,100 minimally invasive surgeries, positioning itself among the international leaders in this field [10]. - The center aims to continue fostering the integration of clinical practice, research, and translational medicine to contribute to the "Healthy China" strategy and improve the management of major cardiovascular diseases [10].

Group 1: Innovative Medical Devices - Beijing Bairen Medical Technology Co., Ltd. received approval for its "Transcatheter Valve-in-Valve System," which is designed for patients with symptomatic heart disease due to the failure of previously implanted surgical bioprosthetic mitral valves [5][6] - The system includes components such as a biological valve, delivery system, balloon dilation catheter, catheter sheath kit, gripping device, and inflation pump, utilizing materials like bovine pericardial leaflets and cobalt-chromium alloy [5][6] - As of now, there are a total of 351 innovative medical devices approved for market in China [6] Group 2: Biodegradable Bone Repair Materials - Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. has received approval for its "Magnesium-based Biodegradable Polymer Bone Repair Material," which is suitable for filling and repairing bone defects in limbs without compromising structural stability [10] - The material is composed of PLGA, β-TCP, and magnesium, manufactured using low-temperature additive manufacturing technology [10] - The company was established in 2013 and focuses on the research and production of new orthopedic implants, cardiovascular stents, and high-tech medical products [10]